Navigation Links
NewCardio Announces Positive Results From Third Clinical Validation Study
Date:8/13/2008

standard deviation of less than 10 milliseconds between the two approaches).

The NCE3 results show excellent agreement with the Company's prior external clinical validation studies (NCE1 and NCE2). Moreover, they extend the clinical validation of QTinno(TM) in at least two important ways. First, ECGs in the NCE3 study had much higher levels of electrical noise and artifacts than ECGs from NCE1 and NCE2 studies. Accordingly, the NCE3 study validates QTinno(TM) performance in a significantly more challenging environment than is typical for early-stage QT assessment. Second, the NCE3 study validates QTinno(TM) performance in an instance where the study drug not only causes substantial QT prolongation and T wave abnormalities, but is also known to induce significant and potentially lethal cardiac arrhythmias.

Branislav Vajdic, Ph.D., President and Chief Executive Officer, commented, "The exceptional accuracy of the QTinno(TM) tool was clearly validated by this third, and most challenging clinical study to date. The evidence unequivocally demonstrates that the QTinno(TM) is not only faster at measuring the QT interval compared to current manual and semi-automated approaches, but that it also provides proven levels of accuracy even in challenging conditions and with complex compounds. We believe it provides an important additional independent validation that will help potential customers recognize the value of NewCardio's cardiac assessment tool. In aggregate, the three independent studies collectively provide NewCardio with a robust clinical validation portfolio that demonstrates QTinno(TM) accuracy and precision in measuring key drug safety metrics across a broad range of compounds, and in comparison to a variety of manual and semi-automated 'gold standard' measurements from three different sources."

Dr. Vajdic continued, "The Company is now actively pursuing commercial validation of QTinno(TM) and is in discussion with potential CRO partners. We al
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
6. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... Nektar Therapeutics (Nasdaq: NKTR ) today announced ... for NKTR-181, a first-in-class, opioid analgesic molecule with ... rate of entry is designed to reduce the euphoria that ... opioid analgesics. 1 In the study data being presented ... "drug liking" and "feeling high" scores and had highly statistically ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
... Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR ... estimates that 353 new, paid Acthar prescriptions for the treatment ... quarter, up 66% from the year ago period and up ... 6,666 vials of the company,s principal drug, H.P. Acthar® Gel, ...
... 2011 - Bayer HealthCare Pharmaceuticals has become aware of a ... and swabsticks manufactured by the Triad Group and marketed under ... wants to ensure that U.S. patients and physicians using Bayer,s ... The recall of the Triad Group alcohol prep products ...
Cached Medicine Technology:Questcor Pharmaceuticals Reports Strong Finish to 2010 2Questcor Pharmaceuticals Reports Strong Finish to 2010 3Questcor Pharmaceuticals Reports Strong Finish to 2010 4Questcor Pharmaceuticals Reports Strong Finish to 2010 5Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 2Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 3
(Date:6/19/2013)... Francisco, CA (PRWEB) June 19, 2013 The ... sized tents is because users can place a 4x8 flood ... clearance boundary space to work around. In addition, Gorilla ... tents. Because they are the tallest, thickest and strongest grow ... new bar for grow tent standards. , Gorilla ...
(Date:6/19/2013)... 19, 2013 The website HealthNewsWires.com has ... resistance, its harmful effects and tips to manage and ... video from HealthNewsWires.com, the author defines insulin resistance ... efficiently remove and process glucose from the bloodstream. ... by all cells, organs and systems of the body ...
(Date:6/19/2013)... June 19, 2013 Tornadoes and their ... Many families who have fallen victim to these deadly ... International Inc. has protected families and corporations from ... Engineering International Inc. believes in the philosophy of providing ... water table, that allows people to stand up, with ...
(Date:6/19/2013)... In honor of women everywhere, Winston-Salem based vein ... women can use to improve their health, especially their ... close attention to their health, as their well-being affects ... body undergoes while pregnant can increase her risk of ... Workman, a leading vein doctor at Novant Health Vein ...
(Date:6/19/2013)... DC (PRWEB) June 19, 2013 ... in the history of managed care. As many ... coverage through the new state-based and federally operated ... for essential health benefits, and examples of premium ... states, industry-leading health business information publisher Atlantic Information ...
Breaking Medicine News(10 mins):Health News:Stealth Grow Tent Brand’s Popularity Rises 2Health News:Effects of Insulin Resistance and How to Increase Insulin Sensitivity Published in New Video by Health News Wire 2Health News:Radius Engineering International Inc. Tornado-Resistant Storm Shelters 2Health News:Novant Health Vein Specialists Promotes Women’s Health with Social Media Campaign 2Health News:New Special Report Provides Comprehensive Overview of New Health Insurance Exchange Marketplaces 2
... drink and fight than females, study finds , WEDNESDAY, ... healthy behaviors, boys, high school team sports might be doing ... teenage boys, participation in team sports may encourage unruly behavior ... the other hand, seem to behave better in organized sports, ...
... than women if spouse is sick, study finds , WEDNESDAY, Nov. ... a marriage, and couples are much more likely to fall apart ... of separation or divorce are six times higher compared to when ... shows. , The researchers did find that couples that have been ...
... need to use the antiviral properly, experts say , WEDNESDAY, ... in a Canadian family developed a strain of the H1N1 ... being given the drug to prevent the disease. , To ... of H1N1 swine flu that were resistant to Tamiflu, which ...
... ... desperate pioneers whose drug use had gotten the better of them every day ... an epilepsy drug could reduce their use of cocaine. In the end, 14 ... final three weeks of the study with no signs of cocaine use on ...
... For Lung Cancer Legislation , WASHINGTON, Nov. 11 ... on Veterans Day and announces the launch of a ... cancer -- the leading cause of cancer death among ... , LCA also announces that major veteran service organizations ...
... The University of Rochester Medical Center has announced ... researchers studying the electrical activity of the heart with ... and developing new electrocardiograph technologies. The Center for ... $2.3 million grant from the National Institutes of Health ...
Cached Medicine News:Health News:Boys' Team Sports May Encourage Bad Behavior 2Health News:Boys' Team Sports May Encourage Bad Behavior 3Health News:Cancer Can Strain Marriages to Breaking Point 2Health News:Tamiflu-Resistant Swine Flu Found in Canadian Father 2Health News:Tamiflu-Resistant Swine Flu Found in Canadian Father 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 2Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 3Health News:Anti-Epileptic Drug Curbs Cocaine Use in First Study Comparing Placebo Dose 4Health News:Lung Cancer Alliance Salutes Veterans 2Health News:New Research Center to Focus on Cardiac Safety and Innovation 2Health News:New Research Center to Focus on Cardiac Safety and Innovation 3
The ACCU-CHEK Spirit insulin pump system offers frequent and precise delivery of the basal rate and rapid infusion of the bolus. The ACCU-CHEK Spirit pump is safe, reliable and easy to program....
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie...
... In ocular fundus perimetry, the visual field ... displayed on the screen. By overlapping the ... you can grasp the correspondence between the ... Digital imaging system enabling practices to totally ...
... to meet the varying needs of todays medical ... use, compact, dual application system that will successfully ... based hair removal. SpaTouch works on all hair ... on nearly all face and body hair., With ...
Medicine Products: